Bolt Biotherapeutics, Inc. (BOLT) |
|
1.93 -0.11 (-5.39%)
|
07-02 16:26 |
|
Open: |
2.01 |
Pre. Close: |
2.04 |
|
High:
|
2.06 |
Low:
|
1.92 |
|
Volume:
|
150,836 |
Market Cap:
|
72(M) |
|
|
|
|
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.06 - 2.07 |
2.07 - 2.08 |
|
Low:
|
1.89 - 1.91 |
1.91 - 1.92 |
|
Close:
|
1.91 - 1.93 |
1.93 - 1.95 |
|
Technical analysis |
as of: 2022-07-01 4:20:31 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.5 One year: 2.86 |
| Support: |
Support1: 1.64 Support2: 1.37 |
| Resistance: |
Resistance1: 2.14 Resistance2: 2.45 |
| Pivot: |
1.91 |
| Moving Average: |
MA(5): 1.95 MA(20): 1.95
MA(100): 2.32 MA(250): 7.06 |
| MACD: |
MACD(12,26): 0 Signal(9): 0  |
| Stochastic oscillator: |
%K(14,3): 63.2 %D(3): 53.9 |
| RSI: |
RSI(14): 50.5 |
| 52-week: |
High: 19.28 Low: 1.38 |
| Average Vol(K): |
3-Month: 315 (K) 10-Days: 559 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BOLT ] has closed below upper band by 46.6%. Bollinger Bands are 41% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Sat, 02 Jul 2022
Usain Bolt Once Recalled Breaking Down in Middle of the Road After Hearing About Legendary Kobe Bryant’s Passing Away News - EssentiallySports
Sat, 02 Jul 2022
Chevy Bolt EUV review: A good value that's getting better - Business Insider
Fri, 01 Jul 2022
Analysis: USC and UCLA bolt for Big Ten. So what’s next for UW and the rest of the Pac-12? - The Seattle Times
Fri, 01 Jul 2022
Chevrolet Is Giving Money Back to Bolt Owners Who Purchased the EV Prior to its Price Cut - Jalopnik
Fri, 01 Jul 2022
Sova's Recon Bolt can be destroyed through impenetrable walls on Breeze in VALORANT - Dot Esports
Fri, 01 Jul 2022
Usain Bolt’s Net Worth in 2022 - ClutchPoints
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
37 (M) |
|
% Held by Insiders
|
1.428e+007 (%) |
|
% Held by Institutions
|
6.8 (%) |
|
Shares Short
|
1,250 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-9.159e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-7 |
|
Return on Assets (ttm)
|
364.1 |
|
Return on Equity (ttm)
|
-32.8 |
|
Qtrly Rev. Growth
|
1.26e+006 |
|
Gross Profit (p.s.)
|
-1.08 |
|
Sales Per Share
|
0.02 |
|
EBITDA (p.s.)
|
-2.19 |
|
Qtrly Earnings Growth
|
-4.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-57 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
95.67 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.62e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
